A Prolonged Treatment Associated With Absent Septum Pellucidum in Neonatal Abstinence Syndrome: A Case Report
Journal of Pediatric Health Care · 2023
DOI: 10.1016/j.pedhc.2023.02.005 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Pediatric Health Care, 2023. Verfasst von Rajapillai L I Pillai und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Neonatal Abstinence Syndrome. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Neonatal abstinence syndrome (NAS) involves a widely variable treatment course among affected individuals. Prognostic indicators that would help predict length of hospital stay and individualize treatment would be valuable to newborns, parents, and hospital staff, including advanced practice registered nurses. We describe a newborn with a prolonged NAS treatment course necessitating high doses of opioids and phenobarbital, found to have an isolated absent septum pellucidum (ASP). We hypothesize a mechanism for an association between an ASP and a difficult NAS treatment course. Should this be substantiated by other cases, it could provide a valuable prognosticator and indicate alternate treatment pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Pillai, R. L. I., He, J., Madore, L., & Murphy, K. (2023). A Prolonged Treatment Associated With Absent Septum Pellucidum in Neonatal Abstinence Syndrome: A Case Report. Journal of Pediatric Health Care. https://doi.org/10.1016/j.pedhc.2023.02.005
Vancouver
Pillai RLI, He J, Madore L, Murphy K. A Prolonged Treatment Associated With Absent Septum Pellucidum in Neonatal Abstinence Syndrome: A Case Report. Journal of Pediatric Health Care. 2023. doi:10.1016/j.pedhc.2023.02.005
BibTeX
@article{Pillai2023,
author = {Pillai, Rajapillai L I and He, Jixi and Madore, Laura and Murphy, Katherine},
title = {A Prolonged Treatment Associated With Absent Septum Pellucidum in Neonatal Abstinence Syndrome: A Case Report},
journal = {Journal of Pediatric Health Care},
year = {2023},
doi = {10.1016/j.pedhc.2023.02.005}
}
EUVIMED